Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Brandt, SD; Elliott, SP; Kavanagh, PV; Dempster, NM; Meyer, MR; Maurer, HH; Nichols, DE
Publisher: Wiley
Languages: English
Types: Article
Subjects: RS, RM
RationaleSubstances based on the N-(2-methoxybenzyl)phenethylamine template ('NBOMe' derivatives) play an important role in medicinal research but some of these derivatives have also appeared as 'research chemicals' for recreational use which has attracted attention worldwide. A major challenge associated with newly emerging substances includes the lack of analytical data and the ability to correctly identify positional isomers.Methods Six N-benzylphenethylamines based on the 2,5-dimethoxy-4-iodophenethylamine structure ('25I') and twelve substituted N-benzyl-5-methoxytryptamines ('5MT') have been prepared and extensively characterized. Techniques used for characterization were gas chromatography/ion trap mass spectrometry in electron and chemical ionization mode, liquid chromatography/diode array detection (DAD), infrared spectroscopy, electrospray high mass accuracy quadrupole time-of-flight tandem mass spectrometry, and triple quadrupole tandem mass spectrometry.ResultsThe characterization of 18 'NBOMe' compounds provided a comprehensive collection of chromatographic and spectral data. Four groups of three positional isomers, i.e. 25I-NB2OMe, 25I-NB3OMe, 25I-NB4OMe, 25I-NB2B, 25I-NB3B, 25I-NB4B and their 5-methoxytryptamine counterparts, were included and assessed for ability to obtain differentiation. Six meta-substituted N-benzyl derivatives of 5-methoxytryptamine (CF3, F, CH3, Cl, I, SCH3) were also studied.Conclusions The implementation of mass spectral techniques was helpful for the differentiation between isomers, for example, when considering the difference in a number of ion ratios. This was considered beneficial in cases where chromatographic separation was only partially achieved under liquid chromatography (LC) conditions. The use of LC/DAD analysis was also found to be valuable for this particular purpose, which confirmed the integrative value of complementary techniques used in areas related to forensic toxicology.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [11] [12] [13] [14] [15] D. E. Nichols, C. D. Nichols. Serotonin receptors. Chem. Rev. 2008, 108, 1614.
    • F. X. Vollenweider, M. F. Vollenweider-Scherpenhuyzen, A. Babler, H. Vogel, D. Hell. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998, 9, 3897.
    • D. E. Nichols. Hallucinogens. Pharmacol. Ther. 2004, 101, 131.
    • A. L. Halberstadt, D. E. Nichols, Serotonin and serotonin receptors in hallucinogen action. In Handbook of Behavioral Neurobiology of Serotonin, Chapter 4.7. (Ed.: C. Müller, B.L. Jacobs), Elsevier/Academic Press, Amsterdam, 2010, pp. 621.
    • A. Shulgin, A. Shulgin, PIHKAL. A chemical love story, Transform Press, BerkeFley, USA, 1991.
    • S. D. Brandt, L. A. King, M. Evans-Brown. The new drug phenomenon. Drug Test. Anal. o2014, 6, 587.
    • L. A. King. New phenethylamines in Europe. Drug Test. Anal. 2014, 6, 808.
    • Hallucinogens recPruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53, 439.
    • EMCDDA-Europol 201e1Annual Report on the implementation of Council Decision 2005/387/JHA. EMCDDA/Europol, Lisbon, 2012. Available at: http://www.emcdda.euroepa.eu/publications/implementationreports/2011 [28 August 201r4].
    • EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA (New drRugsin Europe, 2012). EMCDDA, Lisbon, 2013. Available at: reports/2012 [28 August 2014] e http://www.emcdda.europa.eu/publications/implementationEMCDDA-Europol 2013 Annual Report ovnthe implementation of Council Decision 2005/387/JHA. EMCDDA/Europol, Lisbon, 2014. Available at: http://www.emcdda.europa.eu/publicationis/implementationreports/2013 [28 August 2014]. e w United Nations Office on Drugs and Crime (UNODC) (2013). The challenge of new psychoactive substances. A Report from the Global SMART Programme March 2013. United Nations Publication, Vienna, Austria. Available at: http://www.unodc.org/documents/scientific/NPS_2013_SMART.pdf [05 September 2014].
    • World Health Organization. Thirty-sixth meeting of the Expert Committee on Drug Dependence. 2014. 16−20 June, Geneva, Switzerland. Avialable at: http://www.who.int/medicines/areas/quality_safety/36thecddmeet/en/ [05 September 2014].
    • EMCDDA. Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)- N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances. 2014. Available at: http://www.emcdda.europa.eu/attachements.cfm/att_228239_EN_25INBOMe RAR_with annexes.pdf (22 June 2014).
    • Council of the European Union. 2014/688/EU: Council Implementing Decision of 25 September 2014 on subjecting 4-iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1- (dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article